MANAGEMENT OF STEMI WITH ANTERIOR WALL MOTION ABNORMALITIES USING TRIPLE VERSUS DOUBLE ANTI-THROMBOTIC THERAPY: THE MAGIC MULTICENTER RETROSPECTIVE REGISTRY

摘要

BACKGROUND: The clinical tradition of adding oral anti-coagulation (OAC) to Background therapy in patients with anterior STEMI and new onset antero-apical wall motion abnormalities (WMA) predates the modern reperfusion era. Evidence for the continued pertinence of this practice in the setting of timely primary percutaneous coronary intervention (pPCI) and widespread use of newer P2Y12-inhibitors is lacking. Clinicians are therefore faced with a therapeutic dilemma in balancing ischemic and hemor-rhagic risks that remains unsettled. The objective of this on-going cohort study is to test the hypothesis that dual antiplatelet therapy (DAPT) alone provides a similar net clinical benefit compared to the combination of DAP-T+OAC in these patients.